1. Ekberg H, Tedesco-Silva H, Demirbaş A, Vitko S, Nashan B, et al. Symphony-Comparing standard immunosuppression to low dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. WTA Boston 22-27 June 2006.
2. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked dec¬rease rates over the most recent era. Am J Transplantation 2004;4;378-84.
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, Mcln-tosh MJ, Stablein D. Improved graft survival after renal trans¬plantation in the United States, 1988 to 1996. N Engl J Med
2000;342:605-612.
4. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal
transplantation. N Engl J Med 2002;346:580-90.
5. Marcen R, Pascual J, Teruel JL, Villafruela JJ, Rivera ME, et al. Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss? Transplantation 2001;72:57-62.
6. Marcussen N, Nyengaard J, Christensen S. Compensatory growth of glomeruli is accomplished by an increase number of glomerular capillaries. Lab Invest 1994;70:868-74.
7. Kang DH, Anderson S, Kim YC, Mazalli M, Suga S, Jefferson JA, et al. Impaired angiogenesis in the aging kidney: poten¬tial role of VEGF and TSP-1 in renal disease. Am J Kidney Dis
2001;37:601-11.
8. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, et al. Impaired angiogenesis in the remnant kidney mo¬del: potential role of vascular endothelial growth factor and thrombospondin-1. Am Soc Nephrol 2001;12:1434-37.
9. Bohle A, Mackensen-Haen S, Wehrmann M. Significance of post-glomerular capillaries in the pathogenesis of chronic re¬nal failure. Kidney Blood Press Res 1996;19:191-5.
10. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Ca-
vallo T, et al. The Banff 97 working classification of renal al-
lograft pathology. Kidney Int 1999;55:713-23.
11. Solez K. International standardization of criteria for histologic diagnosis of chronic rejection in renal allografts. Clin Trans¬plant 1994;8:345-50.
12. Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M,
Tolkoff-Rubin NE, et al. Chronic humoral rejection: identifi-
44
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi /Official Journal of the Turkish Society of Nephrology
Renal
Transplantasyond
a Kronik Allogreft Disfonksiyonu 9
cation of antibody mediated chronic allograft rejection by C4d deposits in peritubular capillaries. Am J Soc Nephrol
2001;12:574-82.
13. Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, et
al. Antibody-mediated rejection criteria: An addition to the Banff 97 classification of renal allograft rejection. Am J Trans¬plant 2003;3:708-14.
14. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Delta analysis of posttransplantation tubuloin-terstitial damage. Transplantation 2004;78:434-41.
15. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: Longitudi¬nal assessment by protocol histology. Transplantation
2004;78:557-65.
16. Sudhir K, MacGregor JS, DeMarco T, De Groot CJ, Taylor RN,
Chou TM, et al. Cyclosporine impairs release of endothelium derived relaxing factors in epicardial and resistance coronary
arteries. Circulation 1994;90:3018-23.
17.
Diederic
h D, Skopec J, Diederich A, Dai FX. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994;23:957-61.
18. Moore LC, Mason J, Feld L, Van Liew JB, Kaskel FJ. Effects of
cyclosporine on endothelial albumin leakage in rats. J Am
Soc Nephrol 1992;3:51-7.
19. Kochi S, Takanaga H, Matsuo H, Ohtani H, Naito M, Tsuruo T, et al. Induction of apoptosis in mouse brain capillary en-dothelial cells by cyclosporine A and tacrolimus. Life Sci
2000;66:2255-60.
20. Collins P, Wilkie M, Razak K, Abbot S, Harley S, Bax C, et al.
Cyclosporine and cremaphor modulate von Willabrand factor release from cultured human endothelial cells. Transplantati¬on 1993;56:1218-23.
21. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994;4 (Suppl 1):30-38.
22. Takeda Y, Mitamori I, Wu P, et al. Effects of an endothelin receptor antagonist in rats with cyclosporine induced hyper¬tension. Am J Kidney 1995;26:932-37.
23. Mayer
AD
, Dmitrewski J, Squifflet JP, et al. Multicenter ran¬domized trial comparing tacrolimus (FK506) and cyclospori-ne in the prevention of renal allograft rejection. A report of the European Tacrolimus Multicenter Renal Study Group.
Transplantation 1997;64:436-43.
24. Prisch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A com¬parison of tacrolimus (FK506) and cyclosporine for immuno-suppression after cadaveric renal transplantation. Transplan¬tation 1997;63:977-83.
25. Border WA, Noble NA. Transforming growth factor ,. Am Sci
Med 1995;268-77.
26. Border WA, Noble NA. Transforming growth factor , in tissu¬e fibrosis. N Engl J Med 1994;331:1286-1292.
27. Gellai M. Physiological role of endothelin in cardiovascular and renal hemodynamics: studies in animals. Curr Opin Nep-
hrol Hypertens 1997;6:64-68.
28. Border WA, Noble NA. Interactions of transforming growth factor, and angiotensin II in renal fibrosis. Hypertension
1998;31:181-188.
29. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney trans¬plant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantati¬on 1998;66:1736-40.
30. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD,
Chapman JR. The natural history of chronic allograft nephro-
pathy. N Engl J Med 2003;349:2326-33.
31. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative
Transplant Study. Kidney Int 1998;53:217-221.
32. Kasiske AM, Chakkera H. Successful renal transplantation in American Indians. Transplantation 1998;66:209-14.
33. Geddes CC, Church CC, Collidge T, McCurden EA, Gillespie G, et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003;18:1891-8.
34. Humar A, Kerr S, Gillingham KJ, Matas AJ. Features of acute rejection that increase risk for chronic rejection. Transplanta¬tion 1999;68:1200-1203.
35. Opelz G. Critical evaluation of the association of acute with chronic graft rejection in kidney and heart transplant recipi¬ents. The Collaborative Transplant Study.Transplant Proc
1997;29:73-76.
36. Sijpkens YW, Doxiadis II, Mallat MJ, de Fijter JW, Bruijn JA,
et al. Early versus late acute rejection episodes in renal trans¬plantation. Transplantation 2003;75:204-207.
37. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allog-
raft dysfunction. J Am Soc Nephrol 2005;16:3015-26.
38. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998;9:2129-34.
39. Furness PN, Philpott CM, Chorbadjian MT, Nicholson ML,
Bosmans JL, et al. Protocol biopsy of the stable renal trans¬plant: A multicenter study of methods and complication ra¬tes. Transplantation 2003;76:969-73.
40. Moreso F, Alperovich G, Fulladosa X, Gil-Vernet S, Ibernon M, et al. Histologic findings in protocol biopsies performed in stable renal allografts under different immunosuppressive schedules. Transplant Proc 2003;35:1666-8.
41. Smith KGC, Isbel NM, Catton MG, Leydon JA, Becker GJ,
Walker RG. Suppression of the humoral immune response by micophenolate mofetil. Nephrol Dial Transplant 1998;13:160-4.
42. Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
Transplantation 2003;75:2048-2053.
43. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, et al. A novel approach to the treatment of chronic allog-raft nephropathy. Transplantation 1997;64:1706-1710.
44. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, et al.
Long-term impact of discontinued or reduced calcineurin in¬hibitor in patients with chronic allograft nephropathy. Kidney
Int 2001;59;1567-1573.
45. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Baker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.
Transplantation 1997;63:39-47.
46. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of la¬te rejection. Am J Transplantation 2003;3:68-73.
47. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cib-rik D, Magee JC, et al. Mycophenolate mofetil reduces late re¬nal allograft loss independent of acute rejection. Transplan¬tation 2000;69:2405-2409.
48. Molina MG, Seron D, Moral RG, Carrera M, Sola E, et al.
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
45
0 Chronic Allograft Dysfunction in Renal Transplantati
Thank you for copying data from http://www.arastirmax.com